622 PD-L1 is a potential predictive biomarker for response to RM-1929 treatment in recurrent head and neck squamous cell carcinoma patients
Published date:
11/09/2020
Excerpt:
PD-L1 expression prior to RM-1929 treatment was assessed by immunohistochemistry in 18 out of 30 patients enrolled...These results suggest that rHNSCC patients with lower PD-L1 expression levels may be more responsive to RM-1929 treatment…